CLINICAL_TRIALS
trial_result
· 2020-07-08
Clinical Trial Update: Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma [Phase 1]
Summary
Phase 1 trial update assessing tolerability of a bispecific targeted biologic (IMCgp100) in malignant melanoma has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Immunocore Ltd | Conditions: Malignant Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2020-07-08